Details for Patent: 7,378,508
✉ Email this page to a colleague
Which drugs does patent 7,378,508 protect, and when does it expire?
Patent 7,378,508 protects DIFICID and is included in two NDAs.
Protection for DIFICID has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and twenty-six patent family members in twenty-nine countries.
Summary for Patent: 7,378,508
| Title: | Polymorphic crystalline forms of tiacumicin B |
| Abstract: | The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile ("C. difficile"), Clostridium perfringens ("C. perfringens"), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci. |
| Inventor(s): | Chiu; Yu-Hung (San Diego, CA), Che; Tessie Mary (San Diego, CA), Romero; Alex (San Diego, CA), Ichikawa; Yoshi (San Diego, CA), Shue; Youe-Kong (Carlsbad, CA) |
| Assignee: | Optimer Pharmaceuticals, Inc. (San Diego, CA) |
| Application Number: | 11/831,886 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,378,508 |
|
Patent Claim Types: see list of patent claims | Compound; Dosage form; Composition; |
Drugs Protected by US Patent 7,378,508
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cubist Pharms Llc | DIFICID | fidaxomicin | FOR SUSPENSION;ORAL | 213138-001 | Jan 24, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Cubist Pharms Llc | DIFICID | fidaxomicin | TABLET;ORAL | 201699-001 | May 27, 2011 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,378,508
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1539977 | ⤷ Sign Up | C300727 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1539977 | ⤷ Sign Up | CA 2015 00020 | Denmark | ⤷ Sign Up |
| European Patent Office | 1539977 | ⤷ Sign Up | 92684 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
